Búsqueda de Publicación - Prisma - Unidad de Bibliometría

Publicaciones en la fuente ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Tipo Año Título Fuente
Artículo2024Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIVALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2024Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practiceALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2024Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registryALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2024Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvirALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2023Clinical utility of urinary gluten immunogenic peptides in the follow-up of patients with coeliac disease.ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Editorial2023Editorial: coeliac disease follow-up guided by gluten immunogenic peptides—are we there yet? Authors' replyALIMENTARY PHARMACOLOGY & THERAPEUTICS
Editorial2023Editorial: Feeling better about NASH-Authors' replyALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2023Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: a randomised trial.ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2022A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approachALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2022Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter studyALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2022Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis.ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2021Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term studyALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2021Effectiveness and safety of obeticholic acid in a Southern European multicenter cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acidALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2020Exposure sources, amounts and time course of gluten ingestion and excretion in patients with coeliac disease on a gluten-free dietALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2019Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCUALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2019Increased risk of thiopurine-related adverse events in elderly patients with IBDALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2019Prospective longitudinal study: use of faecal gluten immunogenic peptides to monitor children diagnosed with coeliac disease during transition to a gluten-free dietALIMENTARY PHARMACOLOGY & THERAPEUTICS
Editorial2018Editorial: looking for patients at risk of cirrhosis in the general population-many needles in a haystackALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2018The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesityALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2017Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitisALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2017Simeprevir in combination with sofosbuvir in treatment-naive and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO)ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2016Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological referenceALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2015Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatmentsALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2015Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON studyALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2015Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naive patients with chronic HCV genotype 1 infection (ESSENTIAL II)ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Revisión2014HCV genotype 3 - the new treatment challengeALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2013Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphismALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2013Meta-analysis: pegylated interferon α-2a achieves higher early virological responses than α-2b in chronic hepatitis CALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2012Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failuresALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2012High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication ratesALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2011Meta-analysis: insulin resistance and sustained virological response in hepatitis CALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2011Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patientsALIMENTARY PHARMACOLOGY & THERAPEUTICS
Letter2008Eradication of Helicobacter pylori for the prevention of peptic ulcer rebleedingALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2008Evaluation of Naranjo Adverse Drug Reactions Probability Scale in causality assessment of drug-induced liver injuryALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2007Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patientsALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2007Treatment of chronic hepatitis C genotype 1 with peginterferon-alpha 2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rateALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2006Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patientsALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2006Treatment of chronic hepatitis c genotype 1 with peginterferona2a (40 kda) plus ribavirin under routine clinical practice in spain: early prediction of sustained virological response rateALIMENTARY PHARMACOLOGY & THERAPEUTICS
Artículo2003Three-day intravenous triple therapy is not effective for the eradication of Helicobacter pylori infection in patients with bleeding gastro-duodenal ulcerALIMENTARY PHARMACOLOGY & THERAPEUTICS